Inhibrx Biosciences (INBX) Return on Sales (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Return on Sales data on file, last reported at 1.0% in Q4 2025.

• On a quarterly basis, Return on Sales rose 379.0% year-over-year to 1.0% in Q4 2025; TTM through Dec 2025 was 1.0%, a 1020.0% decrease from a year earlier, with the FY2025 full-year figure at 1.08%, down 8546.0% from the prior year.
• Return on Sales for Q4 2025 stood at 1.0%, up from 1.11% in the prior quarter.
• Over the last five years, Return on Sales for INBX reached as high as 185.8% in Q2 2024 and fell as low as 15.68% in Q2 2023.
• Historically, Return on Sales has averaged 18.55% across 3 years, with a median of 1.0% in 2025.
• Across the five-year window, Return on Sales jumped 20149 bps in 2024 and tumbled 18602 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.56% in 2023, then sank by 750 bps to 4.79% in 2024, then surged by 79 bps to 1.0% in 2025.
• Per Business Quant data, the three most recent Return on Sales figures were 1.0% in Q4 2025, 1.11% in Q3 2025, and 0.22% in Q2 2025.